Table 1.
Strain | Relevant propertiesa | Origin (Reference) |
---|---|---|
D39 | type 2 Avery’s strain | Lanie et al., 2007 |
FP58 | Conjugation recipient. str-41; SmR derivative of D39 | Iannelli et al., 2004 |
Rx1 | Unencapsulated derivative of D39 | Pearce et al., 2002 |
FP10 | Conjugation recipient. ΔcomC, str-41; CmR, SmR; unencapsulated, competence deficient derivative of Rx1 | Santoro et al., 2010 |
FP11 | Conjugation recipient. ΔcomC, nov-1; CmR, NovR; unencapsulated, competence deficient derivative of Rx1 | Santoro et al., 2010 |
BM6001 | Tn5253 donor; cat, tet(M); original clinical strain | Dang-Van et al., 1978 |
DP1322 | Tn5253 donor; cat, tet(M); CmR, TcR; Rx1 derivative transformed with BM6001 DNA | Smith et al., 1981 |
FR24 | Tn5253; cat, tet(M); CmR, TcR, SmR; transconjugant from mating between DP1322 and FP10 | This study |
FR51 | Tn5253; cat, tet(M), Δxis-int of Tn5253; CmR, TcR, SmR; KmR; recombinases (orf78-orf79) deletion mutant of FR24 | This study |
FR82 | Tn5253; cat, tet(M), Δint-xis of Tn5251; CmR, TcR, SmR; SpeR; recombinases (orf21-orf22) deletion mutant of FR24 | This study |
astr-41 indicates a point mutation conferring resistance to streptomycin, while nov-1 indicates a point mutation conferring resistance to novobiocin. Cm, chloramphenicol; Km, kanamycin; Nov, novobiocin; Sm, streptomycin; Tc, tetracycline; Spe, spectinomycin; R, resistance.